Natus Medical (NAS: BABY) reported earnings on Nov. 7. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Natus Medical met expectations on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly and GAAP earnings per share dropped to a loss.
Gross margins expanded, operating margins contracted, net margins dropped.
Natus Medical booked revenue of $80.7 million. The three analysts polled by S&P Capital IQ hoped for revenue of $81.4 million on the same basis. GAAP reported sales were 57% higher than the prior-year quarter's $51.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.07. The two earnings estimates compiled by S&P Capital IQ anticipated $0.14 per share. GAAP EPS were -$0.07 for Q3 compared to $0.01 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 54.8%, 110 basis points better than the prior-year quarter. Operating margin was -6.0%, 650 basis points worse than the prior-year quarter. Net margin was -2.4%, 270 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $95.9 million. On the bottom line, the average EPS estimate is $0.29.
Next year's average estimate for revenue is $296.1 million. The average EPS estimate is $0.60.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,256 members out of 1,287 rating the stock outperform, and 31 members rating it underperform. Among 361 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 351 give Natus Medical a green thumbs-up, and 10 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Natus Medical is hold, with an average price target of $13.50.
Add Natus Medical to My Watchlist.
The article Natus Medical Goes Red originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Natus Medical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.